camrelizumab + apatinib + temozolomide

Camrelizumab + apatinib + temozolomide is a combination therapy that leverages multiple mechanisms to treat cancer. This regimen combines immunotherapy (camrelizumab, a PD-1 inhibitor), anti-angiogenic therapy (apatinib, a VEGFR2 inhibitor), and chemotherapy (temozolomide, an alkylating agent). The combination has shown promising efficacy in clinical trials for various cancers, with each component contributing differently to the overall anti-tumor effect. Camrelizumab enhances immune response against cancer cells, apatinib normalizes tumor blood vessels and improves T cell infiltration, while temozolomide directly damages cancer cell DNA to prevent replication.